188 related articles for article (PubMed ID: 23558894)
1. DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas.
Kamieniak MM; Muñoz-Repeto I; Rico D; Osorio A; Urioste M; García-Donas J; Hernando S; Robles-Díaz L; Ramón Y Cajal T; Cazorla A; Sáez R; García-Bueno JM; Domingo S; Borrego S; Palacios J; van de Wiel MA; Ylstra B; Benítez J; García MJ
Br J Cancer; 2013 Apr; 108(8):1732-42. PubMed ID: 23558894
[TBL] [Abstract][Full Text] [Related]
2. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.
Stefansson OA; Jonasson JG; Johannsson OT; Olafsdottir K; Steinarsdottir M; Valgeirsdottir S; Eyfjord JE
Breast Cancer Res; 2009; 11(4):R47. PubMed ID: 19589159
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic characterization of hereditary epithelial ovarian cancer based on a tissue microarray study.
Muñoz-Repeto I; García MJ; Kamieniak M; Ramón Y Cajal T; Domingo S; Cazorla A; García Donas J; Hernando Polo S; García Sagredo JM; Hernández E; Lacambra C; Saez R; Robles L; Borrego S; Prat J; Palacios J; Benítez J
Histol Histopathol; 2013 Jan; 28(1):133-44. PubMed ID: 23233066
[TBL] [Abstract][Full Text] [Related]
4. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.
George J; Alsop K; Etemadmoghadam D; Hondow H; Mikeska T; Dobrovic A; deFazio A; ; Smyth GK; Levine DA; Mitchell G; Bowtell DD
Clin Cancer Res; 2013 Jul; 19(13):3474-84. PubMed ID: 23633455
[TBL] [Abstract][Full Text] [Related]
5. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
6. Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa.
Staff S; Isola JJ; Johannsson O; Borg A; Tanner MM
Br J Cancer; 2001 Oct; 85(8):1201-5. PubMed ID: 11710835
[TBL] [Abstract][Full Text] [Related]
7. Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.
Weren RD; Mensenkamp AR; Simons M; Eijkelenboom A; Sie AS; Ouchene H; van Asseldonk M; Gomez-Garcia EB; Blok MJ; de Hullu JA; Nelen MR; Hoischen A; Bulten J; Tops BB; Hoogerbrugge N; Ligtenberg MJ
Hum Mutat; 2017 Feb; 38(2):226-235. PubMed ID: 27767231
[TBL] [Abstract][Full Text] [Related]
8. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization.
Jönsson G; Naylor TL; Vallon-Christersson J; Staaf J; Huang J; Ward MR; Greshock JD; Luts L; Olsson H; Rahman N; Stratton M; Ringnér M; Borg A; Weber BL
Cancer Res; 2005 Sep; 65(17):7612-21. PubMed ID: 16140926
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
Jazaeri AA; Yee CJ; Sotiriou C; Brantley KR; Boyd J; Liu ET
J Natl Cancer Inst; 2002 Jul; 94(13):990-1000. PubMed ID: 12096084
[TBL] [Abstract][Full Text] [Related]
10. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K;
J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631
[TBL] [Abstract][Full Text] [Related]
11. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.
Piek JM; Torrenga B; Hermsen B; Verheijen RH; Zweemer RP; Gille JJ; Kenemans P; van Diest PJ; Menko FH
Fam Cancer; 2003; 2(2):73-8. PubMed ID: 14574155
[TBL] [Abstract][Full Text] [Related]
12. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group.
Pharoah PD; Easton DF; Stockton DL; Gayther S; Ponder BA
Cancer Res; 1999 Feb; 59(4):868-71. PubMed ID: 10029077
[TBL] [Abstract][Full Text] [Related]
13. Whole-exome DNA sequence analysis of Brca2- and Trp53-deficient mouse mammary gland tumours.
Francis JC; Melchor L; Campbell J; Kendrick H; Wei W; Armisen-Garrido J; Assiotis I; Chen L; Kozarewa I; Fenwick K; Swain A; Smalley MJ; Lord CJ; Ashworth A
J Pathol; 2015 Jun; 236(2):186-200. PubMed ID: 25692405
[TBL] [Abstract][Full Text] [Related]
14. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.
Vergote I; Banerjee S; Gerdes AM; van Asperen C; Marth C; Vaz F; Ray-Coquard I; Stoppa-Lyonnet D; Gonzalez-Martin A; Sehouli J; Colombo N
Eur J Cancer; 2016 Dec; 69():127-134. PubMed ID: 27821315
[TBL] [Abstract][Full Text] [Related]
15. A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.
Belanger MH; Dolman L; Arcand SL; Shen Z; Chong G; Mes-Masson AM; Provencher D; Tonin PN
J Ovarian Res; 2015 Mar; 8():1. PubMed ID: 25884701
[TBL] [Abstract][Full Text] [Related]
16. Germline mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma.
Kim YT; Nam EJ; Yoon BS; Kim SW; Kim SH; Kim JH; Kim HK; Koo JS; Kim JW
Gynecol Oncol; 2005 Dec; 99(3):585-90. PubMed ID: 16084575
[TBL] [Abstract][Full Text] [Related]
17. Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.
Zweemer RP; Shaw PA; Verheijen RM; Ryan A; Berchuck A; Ponder BA; Risch H; McLaughlin JR; Narod SA; Menko FH; Kenemans P; Jacobs IJ
J Clin Pathol; 1999 May; 52(5):372-5. PubMed ID: 10560359
[TBL] [Abstract][Full Text] [Related]
18. Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease.
Jazaeri AA
Mol Oncol; 2009 Apr; 3(2):151-6. PubMed ID: 19383376
[TBL] [Abstract][Full Text] [Related]
19. Familial vs sporadic ovarian tumors: characteristic genomic alterations analyzed by CGH.
Israeli O; Gotlieb WH; Friedman E; Goldman B; Ben-Baruch G; Aviram-Goldring A; Rienstein S
Gynecol Oncol; 2003 Sep; 90(3):629-36. PubMed ID: 13678737
[TBL] [Abstract][Full Text] [Related]
20. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.
Arts-de Jong M; de Bock GH; van Asperen CJ; Mourits MJ; de Hullu JA; Kets CM
Eur J Cancer; 2016 Jul; 61():137-45. PubMed ID: 27209246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]